Attached files
| file | filename |
|---|---|
| S-1 - SAFECODE DRUG TECHNOLOGIES CORP. | v221470_s1.htm |
| EX-3.2 - SAFECODE DRUG TECHNOLOGIES CORP. | v221470_ex3-2.htm |
| EX-3.1 - SAFECODE DRUG TECHNOLOGIES CORP. | v221470_ex3-1.htm |
| EX-3.3 - SAFECODE DRUG TECHNOLOGIES CORP. | v221470_ex3-3.htm |
| EX-5.1 - SAFECODE DRUG TECHNOLOGIES CORP. | v221470_ex5-1.htm |
| EX-23.1 - SAFECODE DRUG TECHNOLOGIES CORP. | v221470_ex23-1.htm |
| EX-10.1 - SAFECODE DRUG TECHNOLOGIES CORP. | v221470_ex10-1.htm |
SAFECODE DRUG TECHNOLOGIES CORP
Subscription Agreement
SAFECODE DRUG TECHNOLOGIES CORP
Attention: Mr. Klopfer
Re: Prospectus, dated 2011
Dear Mr. Klopfer:
The undersigned investor in this Subscription Agreement hereby acknowledges receipt of the prospectus, dated __________________, 2011, of SAFECODE DRUG TECHNOLOGIES CORP a Delaware Corporation, (the "Prospectus" and the “Company”), and subscribes for the following number of shares upon the terms and conditions set forth in the Prospectus.
The Investor agrees that this Subscription Agreement is subject to availability and acceptance by the Company.
The Investor hereby subscribes for ____________ shares of the Company’s common stock ("Common Stock") at $0.005 per share, for an aggregate purchase price of $____________.
Payment of $______ as payment in full of the purchase price is being made via check directly to SAFECODE DRUG TECHNOLOGIES CORP
If this subscription is rejected by the Company, in whole or in part, for any reason, all funds will be returned within twelve business days of the Company’s receipt such funds, without interest or deduction of any kind.
Purchaser Information:
|
Printed Name:
|
||
|
Signature;
|
||
|
Date:
|
||
|
Address:
|
||
the foregoing Subscription is hereby accepted in full on behalf of SAFECODE DRUG TECHNOLOGIES CORP
Date ___________________.
|
SAFECODE DRUG TECHNOLOGIES CORP
.
|
|
|
By:
|
|
|
Joel Klopfer
|